Kallyope lands $112 million Series C to ride the gut-brain axis for another 3 years
Five years after their launch, Kallyope and the gut-brain axis are headed to the clinic — and they’re getting a new fire hose of cash to do so.
The biotech announced a $112 million in Series C funding that will help bring their lead weight loss drug into the clinic later this year and a drug for inflammatory bowel disease not long after. The syndicate contains a long list of backers, most of whom had previously invested, including The Column Group, Lux Capital, Polaris Partners, Euclidean Capital, Two Sigma Ventures, Illumina Ventures, Alexandria Venture Investments and Bill Gates. Four new investors joined: Casdin, Greenspring and two unnamed institutional investors.